Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2002

View Archived Issues

Antalarmin, a CRF1 antagonist, for the therapy of anxiety

SN-38 induces cell cycle arrest and apoptosis in human testicular cancer cells

Structure of FAAH elucidated

Arzoxifene and LG-100268 effective alone and in combination in a rat breast cancer model

Shigella vaccine is safe and immunogenic in phase I trial

Alliance and Mixture Sciences enter technology license agreement

Statistically significant preliminary results in Visudyne study in minimally classic wet AMD

Fujisawa expands topical Atrisone collaboration with Atrix

VaxGen and Kaketsuken sign agreement for smallpox vaccine development

Efficacy of alicaforsen reported in patients with active Crohn's disease

Antiarrhythmic action of a novel arylpiperazine RSD-992 shown in rats and guinea pigs

CP-461 well tolerated in a phase I trial in patients with advanced cancer

Phase II asthma trial of interferon gamma-1b completes randomization

Initial milestone achieved in Applied Molecular Evolution/Chiron collaboration

AVI BioPharma and International Therapeutics to develop NeuGene compounds for HIV

Drug pipeline for allergic rhinitis

BLA amendment for Xolair includes new data

Phase II trial of VX-148 in psoriasis patients commences in Iceland

Novel inhibitors of cytokine production covered by Boehringer Ingelheim patent

Aventis researchers design novel agents for in vitro and in vivo nucleic acid delivery

Decalactones of fungal origin reported to exhibit antitumor and antiinfective activity

New antithrombotic 5-thio-beta-D-xylopyranose derivatives under study at Fournier

Piperidine-based motilin agonists described by Solvay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...